Group items tagged

Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners in Scotland hosted an event celebrating the collaborative work of the health professions and policy makers in Scotland on reducing the environmental harm from prescribing and medicines use. To share priorities for the Scottish Government, Alpana Mair, Head of Effective Therapeutics and Prescribing spoke and National Clinical Director Jason Leitch appeared virtually. Gillian MacKay MSP, Scottish Greens spokesperson for Health and Social Care also joined in-person. Medicines account for around 25% of the NHS's carbon emissions and have an ecological impact when they enter our wastewater system or our rivers and oceans. Tackling the impact of prescribing will be a key part of meeting the ambition of a net zero NHS Scotland by 2040 at the latest. Together, RCGP Scotland and RPS have held two roundtable events on sustainable prescribing, and in June 2022, released a joint statement calling for a wide range of actions, which was signed by the Academy of Medical Royal Colleges and Faculties in Scotland, the Royal College of Physicians of Edinburgh, the Royal College of Anaesthetists, the College of Radiographers, Royal College of Nursing, Queen's Nursing Institute Scotland and Chartered Society of Physiotherapy. Continuing the work of RPS at the International Forum on Quality and Safety in Healthcare, the event aims to mark an opportunity for health professionals and decision makers alike to join a global movement of sustainability in healthcare, and pledge to continue the important work of cutting the climate impact of medicine use while maintaining the highest level of patient care and safety.

The Royal Pharmaceutical Society (RPS), the professional leadership body for pharmacists and pharmaceutical scientists in Great Britain, has today announced its proposal to transition into a royal college, becoming the Royal College of Pharmacy. This move follows an 18-month independent review of the RPS constitution and governance and is aimed at strengthening the RPS's leadership role to better support its members. The organisation proposes to enhance its core activities in education, assessment, credentialing, and setting professional standards, ultimately benefiting patients and the public. Under the proposed new structure, the RPS's knowledge business, Pharmaceutical Press, would become a wholly owned subsidiary called Pharmaceutical Press Ltd, accountable to the charitable body of the Royal College of Pharmacy. RPS President Professor Claire Anderson said: "Pharmacy is changing rapidly and the expectations placed upon pharmacists and the wider pharmacy team will have profound repercussions in terms of delivering patient care.

A new residential building named after Dr Yusuf Hamied has opened at Christ's College, Cambridge, where the head of the Indian pharma giant, Cipla, was an undergraduate and then PhD chemistry student between 1954 and 1960. In more than 800 years that Cambridge University has been in existence, this is the first time an entire building has been named after an Indian. The "grand opening of Yusuf Hamied Court" at Christ's was presided over by Lord Simon McDonald, the Master of the College, and attracted about 25 leading scientists, mostly chemistry professors. Professor Sir Venkatraman Ramakrishnan, a chemistry Nobel Prize winner and a former president of the Royal Society, was also present at the event earlier this month, as well as Dr Anthony Freeling, the acting vice-chancellor of Cambridge University, and the chemist Dame Mary Archer, wife of the best-selling novelist Jeffrey Archer. Hamied and McDonald posed for photographs in front of the "entirely green" four-storey building, where the 64 rooms for postgraduates and fellows from around the world will rely on heat exchangers, instead of gas.

The Royal Pharmaceutical Society (RPS) has responded to the concerns raised by the Guild of Healthcare Pharmacists (GHP) about their proposals to become a Royal College. On behalf of the Guild Council, Rob Connah, president of GHP, recently wrote an open letter to the RPS seeking clarity on the potential impacts of this transition on career progression, time commitments, and other relevant considerations. In response to the Guild Council's inquiries regarding credentialing, RPS chief executive Paul Bennett emphasised that the key purpose of credentialing is to "protect the public and the integrity of the pharmacy profession through assuring patient-focused pharmacists working at advancing levels of post-registration practice." "Defining and assuring post-registration professional standards is a fundamental activity for a royal college and thus fully aligned with our proposals for change," he added. The RPS highlighted the benefits that credentialing can provide both pharmacists and the system.

In September, the Royal Pharmaceutical Society (RPS), the professional leadership body for pharmacists and pharmaceutical scientists in Great Britain, announced its proposal to transition into a Royal College. This significant step, which came following an 18-month independent review of the RPS constitution and governance, aims to strengthen the RPS's leadership role, with the ultimate goal of delivering greater benefits to patients and the public. In an exclusive interview with Pharmacy Business, Tase Oputu, chair of the RPS English Pharmacy Board, discusses the key reasons behind the proposed changes, the potential impact on pharmacists and patients, and her personal journey as the first Black Chair of the RPS Board. Benefits for pharmacists and patients When asked how this transition would benefit pharmacists and patients, Tase says, "I'm excited about RPS' proposals for change. In my view, becoming a Royal College would elevate the status of the profession and strengthen our ability to raise the profile of pharmacy, advocate for change and advance the safe and effective use of medicines for the benefit of patients and the public."

The Royal Pharmaceutical Society (RPS) has joined the Welsh Royal Colleges Child Health Collaborative (WRCCHC) - a newly established group comprising 20 royal colleges and professional bodies that aims to improve health outcomes for children in Wales. Together they have written to the First Minister of Wales asking how his government will improve child health and support the workforce that care for them. Citing recent reports published by the Academy of Medical Royal Colleges and the Academy of Medical Sciences that highlighted declining health among children, they have warned of the impact of poor child health. The WRCCHC aims to ensure a sharper focus and understanding on the current and necessary support required for babies, children and young people and the workforce they represent. RPS Wales will be represented in the group by Anthony Lewis, Children and Women Lead Pharmacist at Cardiff and Vale University Health Board.

The Royal College of GPs (RCGP) has warned that patients in deprived areas could face even greater difficulty accessing GP services if funding for the Targeted Enhanced Recruitment Scheme (TERS) is withdrawn. In a letter to NHS England, the College is calling for confirmation that TERS will be extended for 2025/26 and beyond. The scheme, launched in 2016, was designed to attract GP trainees to economically disadvantaged areas, where healthcare provision has historically been inadequate. TERS offers a one-off payment of £20,000 to GP trainees who commit to working in hard-to-recruit-to locations. Over the years, the scheme has successfully recruited over 2,000 GPs. However, with funding for 2025/26 yet to be confirmed, the RCGP is worried that it could be cut from April. The College has expressed concern that discontinuing the scheme could "make it even more difficult to recruit GPs to work in deprived and under-doctored areas where patients are already significantly disadvantaged compared to those in more affluent areas of the country."

Dr Nik Kotecha OBE, chairman of Morningside Pharmaceuticals and the Randal Charitable Foundation, has won the Distinguished Alumni Award at Imperial College London's Alumni Awards 2022. The annual awards honour outstanding alumni who have demonstrated sustained excellence in their personal and professional achievements and have made a substantial impact on society. Dr Kotecha, who founded Morningside in 1991, which manufactures and supplies generic and branded medicines to the UK and globally, said: "I'm thrilled to be honoured by the university in this way. "As a child growing up in Leicester my family had very little, but I was fortunate to be given opportunities to gain a good education. After finishing my degree in Newcastle; Professor Steve Ley FRS at Imperial College took a chance in accepting me into his eminent group and this really was the opportunity I needed to forge a career.

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Researchers from King's College London and the University of Helsinki have identified a link between periodontitis (gum disease) and cryptogenic ischemic stroke, which causes a blockage in the blood vessel supplying blood to a region of the brain. The findings, recently published in the Journal of Dental Research, emphasise severe gum disease as a risk factor for young-onset stroke, particularly in patients with no other identifiable risk factors. Dr. Susanna Paju, Periodontology Specialist from the University of Helsinki, led the study in collaboration with Dr. Svetislav Zaric, Clinical Lecturer in Periodontology from King's College London. Dr. Zaric explains the implications of their research: "Stroke remains the second leading cause of death globally. Strikingly, the incidence and prevalence of ischemic stroke have been increasing in the younger population during past decades," she said. "Periodontitis, which involves deep inflammation of the gums due to bacteria under the gumline, can lead to systemic effects as bacteria enter the bloodstream and affect other parts of the body," she added.

Patrick Reynolds is an acclaimed speaker. He speaks about quit-smoking in college lecture programs, universities, hospitals & schools programs. It provides online video chat support for those who wish to quit smoking.

The government has launched a new campaign over social media and radio today (January 10) to encourage pregnant women to take their first, second and third dose of Covid-19 vaccine. Joined by experts at the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM), the campaign highlights the risks of the infection and benefits of vaccination. According to the latest data from the UK Health Security Agency (UKHSA), Covid-19 vaccinations are safe for pregnant women. Department of Health and Social Care (DHSC) chief scientific adviser professor Lucy Chappell, said: "We have extensive evidence now to show that the vaccines are safe and that the risks posed by Covid-19 are far greater," calling upon pregnant women who have yet to have their jabs. The campaign will also run testimonies of pregnant women who have had their jabs.

The General Pharmaceutical Council (GPhC) has appointed a new provider, BTL Group Ltd, to conduct its common registration assessment sittings, which it holds jointly with the Pharmaceutical Society of Northern Ireland (PSNI). GPhC chief executive, Duncan Rudkin, said: "I'm pleased to confirm that we have appointed BTL as the supplier for the common registration assessment for the next 3 years after a thorough tender process. "The information provided by BTL during the tender process has given us the necessary assurance that they can support us in continuing to deliver a fair and robust assessment that tests candidates' ability to register as a pharmacist. We will now work closely with BTL on arrangements for the sittings in 2022, to make sure we can provide a positive experience for candidates." BTL has extensive experience of delivering services to a range of clients, including the Royal College of Paediatrics and Child Health and the Royal College of Ophthalmology. Before BTL, GPhC had a contract with Pearson Vue to conduct online assessment in 2021.

The National Pharmacy Association (NPA) has appointed Paul Rees MBE as its new Chief Executive, with his role commencing on November 27th. Rees, currently serving as the Chief Executive of the Royal College of Psychiatrists and having held various roles throughout his career, will succeed Mark Lyonette, who is retiring, NPA said in a statement. "We anticipate Paul joining the NPA after a thorough recruitment process affirmed his suitability," said Nick Kaye, Chair of NPA. "Throughout his career, including his role at the Royal College of Psychiatrists, he has made a significant impact and achieved concrete changes in healthcare and society. I would also like to express my appreciation to Mark for his work as Chief Executive since 2018. He still has important tasks to complete at the NPA before his retirement." Rees has also held key positions at prominent organisations, including the Ramblers Association, National Housing Federation, Charities Aid Foundation, Association of University Teachers, and the , besides being the Head of Communications at the Home Office.

The Welsh chapter of the Royal Pharmaceutical Society, along with ten other royal colleges and professional bodies, have renewed calls for the urgent transformation of mental health services to address increasing demands on the NHS in Wales. Representatives of the Royal College Mental Health Expert Advisory Group joined members of the Senedd in Cardiff to outline the work of the group over the past year and to explain why a well-trained, fully supported and equipped multi-disciplinary workforce is critical for the development of care for people with mental health conditions. To make sustainable change happen, the group is calling for a greater focus by the Welsh government and NHS Wales on the following: The critical changes needed to improve the delivery and structure of mental health services across Wales in community, hospital and specialist secure settings. Parity of access to mental health services for the most vulnerable patients, ensuring they have equal access opportunities that vulnerable patients would receive for physical health conditions.

Three leading healthcare bodies in Scotland have called for action to reduce the environmental impact caused by medicine prescribing. The Academy of Medical Royal Colleges and Faculties in Scotland, Royal Pharmaceutical Society and the Royal College of General Practitioners Scotland have all urged policymakers to enable a more sustainable approach to prescribing. This includes prioritising the introduction of electronic prescribing across the NHS, introducing the requirement for an environmental impact in NHS medicines procurement and improving the availability of data about the environmental impact of medicines. "We call on Scottish government, including the chief medical officer, to enable the delivery of a realistic medicine approach to prescribing by developing a supportive infrastructure for green social prescribing across Scotland," said the healthcare professionals in a joint statement. They have called on the pharmaceutical industry to make information about the environmental impact of medicines readily available in a standardised data format.

Royal Pharmaceutical Society in England and the Royal College of General Practitioners have published recommendations for the roll-out and success of the GP Community Pharmacist Consultation Service (GP CPCS). These recommendations follow a workshop with stakeholders from pharmacy, general practice and representative bodies, examining ways to maximise the potential of the service and meet growing demand on the health service. The workshop report made five recommendations: The NHS England and Improvement should provide additional investment in local system support and resources to drive the CPCS implementation and uptake between general practice and community pharmacy. National representative bodies should work with NHS E&I to develop national and local engagement and streamline communication plans for CPCS referral pathway. Focus on expanding the role of community pharmacists in the management of minor illness. Evaluation of CPCS service and its impacts on general practice workload, patient outcomes and health inequalities.

In 2023, almost 14,000 people in England are estimated to have died due to excessive waits in emergency departments, averaging more than 260 deaths per week, according to new figures from the Royal College of Emergency Medicine (RCEM). The RCEM estimate is based on a large study of NHS patients published in the Emergency Medicine Journal in 2021, which found one excess death for every 72 patients who spent eight to 12 hours in an A&E department. Following a Freedom of Information audit of NHS trusts, the college has found that 65 per cent of people waiting 12 hours or more in A&E were patients waiting for a hospital bed. NHS data for England revealed that over 1.5 million patients waited 12 hours or more in major emergency departments last year. Based on the RCEM calculation, this indicates that over a million of those patients were waiting for a bed.

In a bid to bolster the educational experience for undergraduate pharmacy students across London, Kingston University has embarked on a groundbreaking project in collaboration with University College London and King's College London. This initiative, fueled by a substantial £1.5 million investment from National Health Services England (NHSE), aims to elevate the quality and consistency of pharmacy placements throughout the capital for new pharmacy entrants. The project is designed to address the evolving standards set forth by the General Pharmaceutical Council (GphC), ensuring that newly-trained pharmacists are well-prepared to meet the demands of their profession. By standardizing and expanding pharmacy placements, the three universities seek to provide students with a comprehensive and diverse range of "experiential learning opportunities".

The Royal College of General Practitioners (RCGP) has warned of a potential 'mass exodus' of qualified GPs due to mounting work pressures. A recent RCGP survey found that over 40 per cent of GPs are unlikely to remain in general practice over the next five years, with a quarter stating it is "very unlikely." The situation is particularly concerning in England, with the highest rate of GPs considering leaving the profession reported to be in the East of England and the South East (47 per cent) and the lowest in the North West (36 per cent). Stress was cited as the main factor for leaving the profession, with more than half of respondents indicating that they find the job too stressful. Additionally, 13 per cent of respondents intend to leave the UK and work overseas. Almost 4 out of 10 GPs said they regularly worked more than 40 hours a week despite fewer than 1 in 10 being contracted to do so. The pressures faced by GPs are so severe that 22 per cent report feeling overwhelmed and unable to cope once or twice a week. The College noted that GPs and their teams have delivered an average of 30 million appointments per month in the past year - over 4 million more each month than in 2019 - despite the number of fully qualified, full-time equivalent GPs decreasing by 601 over the same period.